Recursion Pharmaceuticals (RXRX) Cash from Financing Activities (2020 - 2026)

Recursion Pharmaceuticals has reported Cash from Financing Activities for 7 years, with the latest figure at -$3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 108.56% year-over-year to -$3.5 million; the trailing twelve-month figure through Mar 2026 stood at $477.5 million (up 44.38% YoY), and the FY2025 full-year result was $521.5 million, up 71.49% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$3.5 million, down from $132.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $263.1 million in Q2 2024, with the low at -$3.5 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged $65.7 million across 5 years, with a median of $16.5 million in 2024.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 6848.03% — and 2026, when it tumbled 108.56%.
• Recursion Pharmaceuticals' Cash from Financing Activities stood at $147.3 million in 2022, then slumped by 45.23% to $80.7 million in 2023, then sank by 86.81% to $10.6 million in 2024, then soared by 1140.77% to $132.0 million in 2025, then slumped by 102.63% to -$3.5 million in 2026.
• The last three Cash from Financing Activities figures came in at -$3.5 million (Q1 2026), $132.0 million (Q4 2025), and $251.3 million (Q3 2025), per Business Quant data.